AtaiBeckley Advances BPL-003 to Phase 3 Trials for Treatment-Resistant Depression Following FDA Approval
核心洞察
AtaiBeckley (搜索) received FDA support to advance BPL-003, a mebufotenin benzoate (搜索) nasal spray, into Phase 3 trials for treatment-resistant depression (搜索) following a successful End-of-Phase 2 meeting.
The Phase 3 program includes two pivotal studies (ReConnection-1 and ReConnection-2) designed to evaluate single-dose and two-dose regimens, with trial initiation planned for Q2 2026.
BPL-003 has received Breakthrough Therapy designation from the FDA and demonstrated rapid-acting antidepressant effects in Phase 2b studies.
AtaiBeckley (搜索) Inc. has received FDA support to advance its lead compound BPL-003 into Phase 3 clinical trials for treatment-resistant depression (搜索), marking a significant regulatory milestone for the clinical-stage biotechnology company. The FDA's endorsement came following a successful End-of-Phase 2 meeting in March 2026, where regulators provided constructive feedback on the overall design and key components of the proposed pivotal program.
BPL-003, a proprietary intranasal formulation of mebufotenin benzoate (搜索), has been granted Breakthrough Therapy designation by the FDA and is designed to deliver rapid and durable antidepressant effects from a single dose with a short psychedelic duration. The compound addresses a critical unmet need in treating the millions of people affected by treatment-resistant depression (搜索), a debilitating and chronic condition with limited rapid-acting treatment options.
Phase 3 Program Design
The FDA-approved Phase 3 program consists of two pivotal studies, ReConnection-1 and ReConnection-2, to be conducted in parallel. Both trials will include a 12-week, randomized, double-blind, placebo-controlled core study followed by a 52-week open-label extension.
ReConnection-1 will enroll approximately 350 participants across three treatment arms evaluating single doses of 8 mg BPL-003, 4 mg BPL-003, and placebo in a 2:1:2 randomization. This trial is designed to replicate and extend the treatment response observed in Phase 2b studies while further characterizing the dose-response relationship.
ReConnection-2 will enroll approximately 300 participants in a two-dose design, administering BPL-003 or placebo on Day 1 and Day 15 across two arms randomized 1:1. This study aims to investigate whether a two-dose induction model increases the magnitude and durability of initial response.
The primary endpoint for both pivotal trials will be the change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Week 4, comparing the 8 mg BPL-003 treatment arm to placebo. The open-label extension will allow participants to receive individualized 8 mg BPL-003 retreatment at 8- or 12-week intervals, subject to pre-specified eligibility criteria, with the goal of maintaining remission and assessing long-term safety.
Clinical Integration and Treatment Model
According to Kevin Craig, M.D., Chief Medical Officer at AtaiBeckley (搜索), the Phase 3 program is intentionally designed to reflect real-world interventional psychiatry settings. The treatment model features a short, approximately 2-hour in-clinic experience with the potential for only a handful of treatments per year, directly addressing significant barriers facing patients and providers.
"If approved, BPL-003 could fit seamlessly within existing interventional psychiatry workflows while offering compelling practice economics that support broad, sustainable uptake," Craig stated.
Expanded Pipeline Progress
Beyond BPL-003, AtaiBeckley (搜索) reported positive results from its exploratory Phase 2a trial of EMP-01, an oral R-enantiomer of MDMA, in social anxiety disorder (搜索). The randomized, double-blind, placebo-controlled study met its primary safety and tolerability objective while demonstrating clinically meaningful improvements across key efficacy measures.
Key findings from the EMP-01 trial included a clinically meaningful placebo-adjusted least squares mean reduction of 11.85 points on the Liebowitz Social Anxiety Scale at Day 43, with a Hedges' g effect size of 0.45 and p-value of 0.036. The study also showed a 49% responder rate on the Clinician Global Impression-Improvement scale versus 15% for placebo, corresponding to a Number Needed to Treat of 2.95.
The company's pipeline also includes VLS-01, a dimethyltryptamine buccal film for treatment-resistant depression (搜索), with Phase 2 Elumina study topline data anticipated in the second half of 2026.
Financial Position and Timeline
AtaiBeckley (搜索) reported cash, cash equivalents, and short-term securities of $220.7 million as of December 31, 2025, providing a runway expected to fund operations into 2029. This financial position supports the company through planned early-2029 topline readouts from both Phase 3 pivotal studies.
The company plans to initiate the BPL-003 Phase 3 program in Q2 2026, with topline data from both ReConnection studies anticipated by early 2029. Additional near-term milestones include topline data from the VLS-01 Phase 2 study in the second half of 2026 and initial data from a Phase 2a BPL-003 Part 4 cohort evaluating a two-dose induction regimen in Q4 2026.
CEO Srinivas Rao emphasized the significance of the FDA guidance, stating, "This feedback builds on our compelling Phase 2b data as well as the Breakthrough Therapy Designation granted to BPL-003 in October 2025 and firmly positions us to advance a robust Phase 3 clinical program designed to maximize the probability of regulatory and commercial success."